Astellas Pharma (DB:YPHA) - Aandelenkoers, Nieuws & Analyse

YPHA Overzicht aandelen

Astellas Pharma Inc. produceert, verkoopt, importeert en exporteert farmaceutische producten in Japan en internationaal. Meer informatie

YPHA fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	3/6
Prestaties in het verleden	3/6
Financiële gezondheid	4/6
Dividenden	3/6

Beloningen

Verhandeld tegen 65.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 25.59% per jaar groeien

De winst groeide het afgelopen jaar met 43.7%

Risicoanalyse

Het dividend van 4.71% wordt niet goed gedekt door de winst of de vrije kasstromen

Grote eenmalige posten die de financiële resultaten beïnvloeden

Heeft een hoog schuldenniveau

Astellas Pharma Inc. Concurrenten

Merck KGaA

XTRA:MRK

€62.2b

Dermapharm Holding

XTRA:DMP

€2.0b

PharmaSGP Holding

XTRA:PSG

€287.8m

Sartorius

XTRA:SRT3

€13.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Astellas Pharma
Historische aandelenkoersen
Huidige aandelenkoers	JP¥9.35
52 Week Hoogtepunt	JP¥11.50
52 Week Laag	JP¥8.40
Bèta	0.22
11 maand verandering	-9.22%
3 maanden verandering	-14.22%
1 Jaar Verandering	-13.43%
33 jaar verandering	-34.15%
5 jaar verandering	n/a
Verandering sinds IPO	-36.39%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	YPHA	DE Pharmaceuticals	DE Markt
7D	-2.1%	1.4%	0.8%
1Y	-13.4%	-18.4%	9.1%

Rendement versus industrie: YPHA overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -18.4 % opleverde.

Rendement versus markt: YPHA presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 9.1 % opleverde.

Prijsvolatiliteit

Is YPHA's price volatile compared to industry and market?
YPHA volatility
YPHA Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: YPHA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van YPHA is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1923	14,754	Naoki Okamura	www.astellas.com

Astellas Pharma Inc. produceert, verkoopt, importeert en exporteert farmaceutische producten in Japan en daarbuiten. Het bedrijf levert XTANDI, een behandeling voor prostaatkanker; XOSPATA, een behandeling voor patiënten met recidief of refractair acute myeloïde leukemie met een FLT3-mutatie; en PADCEV, een behandeling voor patiënten met uitgezaaide urotheliale kanker. Het biedt ook Evrenzo, een behandeling voor bloedarmoede die gepaard gaat met chronische nierziekte; Betanis/Myrabetriq/BETMIGA, een behandeling voor overactieve blaas; en Prograf en Advagraf/Graceptor/ASTAGRAF XL immunosuppressiva.

Astellas Pharma Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Astellas Pharma zich tot de beurswaarde?
YPHA fundamentele statistieken
Marktkapitalisatie	€17.39b
Inkomsten(TTM)	€338.39m
Inkomsten(TTM)	€10.95b

51.4x

Koers/Winstverhouding

1.6x

P/S-verhouding

Is YPHA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
YPHA resultatenrekening (TTM)
Inkomsten	JP¥1.77t
Kosten van inkomsten	JP¥322.95b
Brutowinst	JP¥1.45t
Overige uitgaven	JP¥1.39t
Inkomsten	JP¥54.75b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	30.58
Brutomarge	81.78%
Nettowinstmarge	3.09%
Schuld/Eigen Vermogen Verhouding	61.2%

Hoe presteerde YPHA op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.7%

Huidig dividendrendement

350%

Uitbetalingsratio

YPHA Overzicht aandelen

Beloningen

Risicoanalyse

Astellas Pharma Inc. Concurrenten

XTRA:MRK

€62.2b

XTRA:DMP

€2.0b

XTRA:PSG

€287.8m

XTRA:SRT3

€13.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Recent updates

Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy

Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S

Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024

Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant)

Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer

Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY

European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol

U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children

Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials

Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab

Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023

Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for Fezolinetant

Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial

Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for Zolbetuximab

Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to Menopause

Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.S

Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023

Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).